For informational and research purposes only. Not medical advice. Content is aggregated from public sources. Always consult a qualified healthcare provider.
Performance & Growth Hormone · Comparison

CJC-1295 / Ipamorelin Stack vs Sermorelin

A neutral, side-by-side comparison of two performance & growth hormone peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.

CJC-1295 / Ipamorelin StackSermorelin
CategoryPerformance & Growth HormonePerformance & Growth Hormone
Also known asCJC-1295 Ipamorelin, Mod GRF 1-29 Ipamorelin, CJC Ipa stack, CJC-1295 without DAC with Ipamorelin, GHRH GHRP combinationGHRH 1-29, GRF 1-29 NH2, Geref
EvidenceFDA-approvedFDA-approved
Dosing range100mcg each–300mcg each mcg, once daily before sleep (or 2–3x daily for more aggressive protocols)100mcg–500mcg mcg, once daily (before sleep)
AdministrationSubcutaneous injection (both compounds), Administered together in the same injectionSubcutaneous injection
Key side effectsWater retention (mild, common), Tingling or numbness in hands/feet (transient), Headache (usually first 1–2 weeks), Fatigue or increased sleepiness (often desired at night dose)Injection site redness, Headache, Flushing, Dizziness
Cited sources2 references1 reference

Key differences

  • Administration: CJC-1295 / Ipamorelin Stack — Subcutaneous injection (both compounds), Administered together in the same injection; Sermorelin — Subcutaneous injection.
  • Frequency: CJC-1295 / Ipamorelin Stack is typically once daily before sleep (or 2–3x daily for more aggressive protocols); Sermorelin is once daily (before sleep).
  • Research depth: this profile cites 2 sources for CJC-1295 / Ipamorelin Stack vs 1 for Sermorelin.

How each works

CJC-1295 / Ipamorelin Stack

CJC-1295 without DAC (Mod GRF 1-29) stimulates GHRH receptors on the pituitary, increasing the amplitude of GH pulses. Ipamorelin independently triggers GH release via the ghrelin receptor (GHS-R1a) with high selectivity — minimal cortisol, prolactin, or aldosterone co-elevation. The combination exploits two separate receptor pathways to produce synergistic GH output. Animal and human studies on each compound individually confirm GH and IGF-1 elevation. The combination is extrapolated from mechanistic research and is the most studied protocol in the peptide research community.

Sermorelin

Sermorelin works by binding pituitary GHRH receptors to stimulate GH secretion within the body's natural feedback loop. Unlike synthetic GH, it does not suppress endogenous production. Clinical studies show improved body composition, sleep quality, and IGF-1 levels in GH-deficient adults. Its short half-life (~10 min) means it requires daily dosing.

Read the full CJC-1295 / Ipamorelin Stack profileRead the full Sermorelin profile

This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.